The Directors of Regent Pacific Group Limited reported that Orient EuroPharma Co., Ltd. ("OEP"), the Group's commercial strategic partner for Taiwan, Hong Kong Special Administrative Region Macau Special Administrative Region ("Macau") and other select countries in Asia, has launched FortacinTM, the Group's prescription treatment for premature ejaculation, for sale in Hong Kong from this month. OEP has also informed the Group that it expects to launch FortacinTM in Macau in March 2021 and in Taiwan (its home market) in April 2021. The Group will generate a low teens royalty of OEP's net sales of FortacinTM in these markets.

This marks a pivotal moment for the Group in realising its strategic goal of offering FortacinTM, through OEP, in its home market of Hong Kong. The Group also informed the shareholders that Wanbang Biopharmaceutical Group Co., Ltd., the Company's commercial strategic partner for China, has appointed a leading contract research organisation to undertake the randomised clinical trial in China. The randomised clinical trial is due to commence in April /May 2021, subject to the approval from National Medical Products Administration.

The Group is in early discussions with a potential partner for "out licensing" the rights to FortacinTM for Japan. While these developments are indeed exciting, it is not possible to determine with accuracy the timing of completion of such discussions, and no assurance can be given that negotiations will lead to a binding Licensing agreement(s).